A Phase 1 Pharmacokinetic Study of Oral IXAZOMIB (MLN9708) in Patients With Advanced Solid Tumors or Hematologic Malignancies With Varying Degrees of Liver Dysfunction

This is a phase 1, 2-part, pharmacokinetic study in patients with advanced solid tumors or hematologic malignancies and varying degrees of liver dysfunction (normal function, moderate hepatic impairement or severe hepatic impairment) as defined by the National Cancer Institute (NCI) Organ Dysfunction Working Group.

本研究为一项针对晚期实体瘤或血液系统恶性肿瘤患者的I期两部分药代动力学研究，受试者的肝功能不全程度符合美国国家癌症研究所（National Cancer Institute, NCI）器官功能障碍工作组的判定标准，涵盖肝功能正常、中度肝功能损害及重度肝功能损害三类人群。